Login to Your Account



First flesh-eating bug drug passes futility analysis in pivotal ph III

By Marie Powers
News Editor

Tuesday, May 23, 2017

Encouraged but still cautious, Dan Teleman, CEO of Atox Bio Ltd., was careful not to raise expectations about the eventual outcome of the ongoing phase III ACCUTE.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription